Lack of Association Between Dexamethasone and Long-Term Survival After Non-Small Cell Lung Cancer Surgery.

OBJECTIVE To evaluate the association between the use of intraoperative dexamethasone with an increase in recurrence-free survival (RFS) and overall survival (OS) after non-small cell lung cancer (NSCLC) surgery. DESIGN This was a propensity score-matched (PSM) retrospective study. SETTING Single academic center. PARTICIPANTS The study comprised patients with stage I through IIIa NSCLC. Patients were excluded if they were younger than 18 years, had missing data, and died within 30 days after surgery. MEASUREMENTS AND MAIN RESULTS Primary outcomes of the study were RFS and OS. The data were PSM. RFS and OS were evaluated using univariate and multivariate Cox proportional hazards models after PSM to assess the association between intraoperative dexamethasone use and the primary outcomes. A p value of<0.05 was considered statistically significant. After PSM, 436 patients were included in each treatment group. Adjusting for significant covariates, the multivariate analysis demonstrated no association between the use of dexamethasone and RFS (hazard ratio [95% confidence interval]: 0.98 [0.78-1.24]; p = 0.915). The multivariate analysis also demonstrated no association between the administration of dexamethasone and OS (hazard ratio [95% confidence interval]: 1.08 [0.81-1.44]; p = 0.58). CONCLUSIONS This study demonstrated that intraoperative dexamethasone administration to NSCLC patients was not associated with a significant impact on RFS and OS. The results were similar to a previous study on ovarian cancer patients. A randomized controlled study should be conducted to confirm the results of this study.

[1]  Y. Jeon,et al.  TTF-1 mRNA-positive circulating tumor cells in the peripheral blood predict poor prognosis in surgically resected non-small cell lung cancer patients. , 2011, Lung cancer.

[2]  B. Chortkoff,et al.  Factors Associated with Improved Survival after Resection of Pancreatic Adenocarcinoma: A Multivariable Model , 2015, Anesthesiology.

[3]  R. Bataille,et al.  Dexamethasone-induced cell death is restricted to specific molecular subgroups of multiple myeloma , 2015, Oncotarget.

[4]  R. Mehran,et al.  Perioperative neutrophil:lymphocyte ratio and postoperative NSAID use as predictors of survival after lung cancer surgery: a retrospective study , 2015, Cancer medicine.

[5]  Y. M. Lee,et al.  Glucocorticoids suppress hypoxia‐induced COX‐2 and hypoxia inducible factor‐1α expression through the induction of glucocorticoid‐induced leucine zipper , 2014, British journal of pharmacology.

[6]  R. McCarthy,et al.  Perioperative Single Dose Systemic Dexamethasone for Postoperative Pain: A Meta-analysis of Randomized Controlled Trials , 2011, Anesthesiology.

[7]  J. Hogg,et al.  Glucocorticoid-induced granulocytosis: contribution of marrow release and demargination of intravascular granulocytes. , 1998, Circulation.

[8]  G. Laurent,et al.  Antiproliferative effect of dexamethasone in the MCF-7 breast cancer cell line , 2015, Molecular medicine reports.

[9]  O. Zmora,et al.  A New Approach to Reducing Postsurgical Cancer Recurrence: Perioperative Targeting of Catecholamines and Prostaglandins , 2012, Clinical Cancer Research.

[10]  L. Rasmussen,et al.  The association of perioperative dexamethasone, smoking and alcohol abuse with wound complications after laparotomy , 2014, Acta anaesthesiologica Scandinavica.

[11]  D. Sessler,et al.  Is Dexamethasone Associated with Recurrence of Ovarian Cancer? , 2014, Anesthesia and analgesia.

[12]  G. Bepler,et al.  Glucocorticoid Receptor Status Is a Principal Determinant of Variability in the Sensitivity of Non–Small-Cell Lung Cancer Cells to Pemetrexed , 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[13]  A. Jemal,et al.  Cancer statistics, 2014 , 2014, CA: a cancer journal for clinicians.

[14]  Yi Lin,et al.  Systemic immune suppression in glioblastoma: the interplay between CD14+HLA-DRlo/neg monocytes, tumor factors, and dexamethasone. , 2010, Neuro-oncology.

[15]  A. Vaporciyan,et al.  Perioperative blood transfusions and survival in patients with non-small cell lung cancer: a retrospective study , 2013, BMC Anesthesiology.

[16]  Bingshu E. Chen,et al.  Gemcitabine/dexamethasone/cisplatin vs cytarabine/dexamethasone/cisplatin for relapsed or refractory aggressive-histology lymphoma: cost-utility analysis of NCIC CTG LY.12. , 2015, Journal of the National Cancer Institute.

[17]  Maximilian Reichert,et al.  EMT and Dissemination Precede Pancreatic Tumor Formation , 2012, Cell.

[18]  S. Han,et al.  Dexamethasone inhibits hypoxia-induced epithelial-mesenchymal transition in colon cancer. , 2015, World journal of gastroenterology.

[19]  R. Sapolsky,et al.  How do glucocorticoids influence stress responses? Integrating permissive, suppressive, stimulatory, and preparative actions. , 2000, Endocrine reviews.

[20]  G. Haegeman,et al.  The interplay between the glucocorticoid receptor and nuclear factor-kappaB or activator protein-1: molecular mechanisms for gene repression. , 2003, Endocrine reviews.

[21]  A. Nicholson,et al.  Neutrophil/lymphocyte ratio and its association with survival after complete resection in non-small cell lung cancer. , 2009, The Journal of thoracic and cardiovascular surgery.

[22]  Jianrong Guo,et al.  Impact of allogenic and autologous transfusion on immune function in patients with tumors. , 2014, Asian Pacific journal of cancer prevention : APJCP.

[23]  E. Rosenne,et al.  In vivo suppression of NK cell cytotoxicity by stress and surgery: Glucocorticoids have a minor role compared to catecholamines and prostaglandins , 2014, Brain, Behavior, and Immunity.

[24]  Ben Tran,et al.  Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. , 2014, Journal of the National Cancer Institute.

[25]  R. McCarthy,et al.  Dexamethasone to Prevent Postoperative Nausea and Vomiting: An Updated Meta-Analysis of Randomized Controlled Trials , 2013, Anesthesia and analgesia.

[26]  Effects of Surgery, General Anesthesia, and Perioperative Epidural Analgesia on the Immune Function of Patients With Non–Small Cell Lung Cancer , 2014 .

[27]  F. Sista,et al.  Dexamethasone for the prevention of recurrent laryngeal nerve palsy and other complications after thyroid surgery: a randomized double-blind placebo-controlled trial. , 2013, JAMA otolaryngology-- head & neck surgery.

[28]  S. Steinberg,et al.  Treatment With Carfilzomib-Lenalidomide-Dexamethasone With Lenalidomide Extension in Patients With Smoldering or Newly Diagnosed Multiple Myeloma. , 2015, JAMA oncology.

[29]  H. Kuerer,et al.  Innate immune function after breast, lung, and colorectal cancer surgery. , 2015, The Journal of surgical research.

[30]  J. Machiels,et al.  Neutrophil:Lymphocyte Ratio and Intraoperative Use of Ketorolac or Diclofenac are Prognostic Factors in Different Cohorts of Patients Undergoing Breast, Lung, and Kidney Cancer Surgery , 2013, Annals of Surgical Oncology.

[31]  P. Forgez,et al.  Glucocorticoid receptor and breast cancer , 2011, Breast Cancer Research and Treatment.

[32]  D. Sessler,et al.  Effects of Supplemental Oxygen and Dexamethasone on Surgical Site Infection: A Factorial Randomized Trial , 2016 .